Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 6/20 | 0.31 |
| ▸ | DYRK3 | O43781 | 5/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.31 |
| ▸ | CDK2 | P24941 | 5/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.31 |
| ▸ | CDK9 | P50750 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721379 | 0.78 | ALDH1A1 (0.43) | MKNK1ALDH1A1KDM4ESMN1; SMN2TNF | |
| SCHEMBL3108672 | 0.74 | AKT1 (0.41) | ALDH1A1KDM4ESMN1; SMN2TNFNTRK1 | |
| SCHEMBL3115930 | 0.74 | NTRK1 (0.50) | MKNK1ALDH1A1KDM4ESMN1; SMN2TNF | |
| SCHEMBL1745899 | 0.73 | DYRK1A (0.41) | ALDH1A1KDM4ESMN1; SMN2TNFNTRK1 | |
| SCHEMBL1394183 | 0.72 | AKT1 (0.40) | MKNK1ALDH1A1KDM4ESMN1; SMN2TNF | |
| SCHEMBL3721378 | 0.71 | ALDH1A1 (0.37) | ALDH1A1KDM4ESMN1; SMN2TNFNTRK1 | |
| SCHEMBL3726451 | 0.70 | FYN (0.40) | ALDH1A1KDM4ESMN1; SMN2NTRK1DYRK1A | |
| SCHEMBL3724143 | 0.70 | GAA (0.38) | ALDH1A1KDM4ESMN1; SMN2NTRK1AKT1 | |
| SCHEMBL18817029 | 0.69 | KDM4E (0.44) | MKNK1ALDH1A1KDM4ESMN1; SMN2TNF | |
| SCHEMBL477062 | 0.69 | KDM4E (0.44) | MKNK1ALDH1A1KDM4ESMN1; SMN2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-25 | — | — | US | disclosed |
| EP-2398802-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010070237-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | CSNK2A1, CSNK1A1, CSNK2A2 | MKNK1 200/4885ALDH1A1 2714/4885KDM4E 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.